Novo shares on track for biggest monthly fall since 2002, investor worries grow
Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...
Novo Nordisk On Pace for Lowest Close Since March 2023 — Data Talk
Novo Nordisk A/S Sponsored ADR Class B (NVO) is currently at $69.91, down $1.82 or 2.54% --Would be lowest close since March 17, 2023, when it closed at $69.72 --Currently down seven consecutive days; ...
FoodNavigator15h
Should big pharma Novo Nordisk’s UPF interest worry food?
Nova 2.0 has been kicked into the reeds after nutritionists kicked up a stink, but Novo Nordisk seems adamant to develop a ...
Is Novo Nordisk Stock a Buy?
Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...
Novo Nordisk to pay $2 billion for new weight loss drug
Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...
Novo Nordisk price target lowered to DKK 610 from DKK 725 at Berenberg
Berenberg analyst Kerry Holford lowered the firm’s price target on Novo Nordisk (NVO) to DKK 610 from DKK 725 and keeps a Hold rating on the ...
Step Aside, Novo Nordisk. This Is Europe’s No. 1 Company Now.
The two stocks have been trending in different directions for months. Here's what that says about the broader market.
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...